$HSIC

HENRY SCHEIN INC

Henry Schein distributes dental and medical products and provides services and technology to health care providers. Its Global Distribution and Value-Added Services segment supplies dental merchandise and equipment, medical products, financial services, continuing education, consulting and other services. Global Specialty Products manufactures, markets and sells dental implants, biomaterials, endodontic, orthodontic and orthopedic products, and other health care-related products and services. Global Technology develops and distributes practice management software, e-services and other technology-enabled products for health care providers. Henry Schein makes money from product sales and fees for services and software. It is headquartered in Melville, New York.

AlphAI earnings readthird quarter 2026 · NOV 3HENRY SCHEIN REPORTS STRONG 2026 THIRD QUARTER AND RAISES FY2026 GUIDANCEVerdict: strong

Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.

0
1
5

No SEC Form 4 filings for $HSIC in the last 30 days.

See all $HSIC insider activity →

Henry Schein revises non-GAAP reporting, lowers EPS guidance

Henry Schein (HSIC) will exclude acquisition-related remeasurement gains from non-GAAP results starting Q4 2026, lowering fiscal 2026 EPS guidance to $5.42-$5.48 from $5.50-$5.56. The change affects reporting of gains from acquiring controlling interests. GAAP results and other guidance, including sales growth of 4.5%-5.5%, remain unchanged.

HENRY SCHEIN UPDATES PRESENTATION

HENRY SCHEIN INC (HSIC) filed an SEC Form 8-K — Regulation FD Disclosure. -1- more FOR IMMEDIATE RELEASE HENRY SCHEIN UPDATES PRESENTATION OF NON-GAAP FINANCIAL MEASURES ● Company will exclude acquisition-related remeasurement gains from non-GAAP financial results. This change better reflects underlying operating performance and improves comparability

HSIC sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 6 news stories mentioning HSIC (HENRY SCHEIN INC). Coverage has skewed bearish: 0 bullish, 1 neutral, and 5 bearish.

Recent HSIC coverage spans financial news and earnings.

What's driving HSIC

AlphAI scores every news story that mentions HSIC with an AI model for sentiment and relevance, and aggregates insider trades from HENRY SCHEIN INC's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $HSIC

Score

Henry Schein revises non-GAAP reporting, lowers EPS guidance

Henry Schein (HSIC) will exclude acquisition-related remeasurement gains from non-GAAP results starting Q4 2026, lowering fiscal 2026 EPS guidance to $5.42-$5.48 from $5.50-$5.56. The change affects reporting of gains from acquiring controlling interests. GAAP results and other guidance, including sales growth of 4.5%-5.5%, remain unchanged.

$HSICMedGuidance· lower · $5.42–$5.48

HENRY SCHEIN UPDATES PRESENTATION

HENRY SCHEIN INC (HSIC) filed an SEC Form 8-K — Regulation FD Disclosure. -1- more FOR IMMEDIATE RELEASE HENRY SCHEIN UPDATES PRESENTATION OF NON-GAAP FINANCIAL MEASURES ● Company will exclude acquisition-related remeasurement gains from non-GAAP financial results. This change better reflects underlying operating performance and improves comparability

CareQuest and Henry Schein Launch BRIDGE Health Network

CareQuest Institute and Henry Schein (HSIC) launched the BRIDGE Health Network to integrate dental and medical care. The pilot will screen patients for health risks, including diabetes, during routine dental visits. Henry Schein will implement the pilots and provide support, while CareQuest will analyze data. The initiative aims to improve early detection and preventive care, potentially saving the U.S. healthcare system up to $100 million annually.

$HSICMedAI 8/10

Why is Henry Schein stock sliding today?

Henry Schein (HSIC) stock fell 5% after Q3 2026 results beat earnings estimates ($1.56 EPS vs. $1.36) but missed revenue forecasts ($3.47B vs. $3.48B). Investors focused on one-time tariff benefits and organic growth concerns. CEO Fred Lowery announced Q4 investment plans, raising margin uncertainty. The company raised full-year EPS guidance to $5.50–$5.56. The decline was driven by company-specific factors, not broader market trends.

Analysts Offer Insights on Healthcare Companies: Nektar Therapeutics (NKTR), Roche Holding AG (OtherRHHVF) and Henry Schein (HSIC)

Analysts updated ratings for Nektar Therapeutics (NKTR), Roche Holding AG (RHHVF), and Henry Schein (HSIC). UBS gave NKTR a Hold rating with a $53 target; consensus is $132.70. Jefferies maintained a Sell on RHHVF with a CHF250 target; consensus is $444.60. Leerink Partners kept a Hold on HSIC with a $89 target; consensus is $101.23.

Related tickers